Loading...
Management of bacteraemia (SAB) in the oncology patient: Further evidence supports prompt removal of central venous catheters and shorter duration of intravenous antimicrobial therapy.
Dunne, Colum P Ryan, Phelim Connolly, Roisin Dunne, Suzanne S Kaballo, Mohammed A Powell, James Woulfe, Bernie O'Connell, Nuala H Gupta, Rajnish K
Dunne, Colum P
Ryan, Phelim
Connolly, Roisin
Dunne, Suzanne S
Kaballo, Mohammed A
Powell, James
Woulfe, Bernie
O'Connell, Nuala H
Gupta, Rajnish K
Citations
Altmetric:
Advisors
Editors
Other Contributors
Departments
Date
2020-02-01
Date Submitted
Keywords
CVC
Central venous catheters
ONCOLOGY
SAB
Staphylococcus aureus bacteraemia
THERAPY
Central venous catheters
ONCOLOGY
SAB
Staphylococcus aureus bacteraemia
THERAPY
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Alternative Titles
Publisher
Abstract
Staphylococcus aureus bacteraemia (SAB) is associated with relatively high risk of complications and high levels of mortality. Internationally, SAB management guidelines lack consensus and especially so regarding oncology patients. This is likely a reflection of insufficient randomised control trials (RCT) and the diversity of SAB patient populations. However, there are 2011 guidelines recommending a minimum of 14 days of appropriate IV antibiotic therapy for SAB.
Language
en
Citation
ISSN
eISSN
2590-0889
ISBN
DOI
10.1016/j.infpip.2020.100037
PMID
34368689